Lytic peptides form the cornerstone of the body’s defence against a broad spectrum of harmful micro-organisms – from bacteria and fungi to viruses and protozoa. Lytic peptides act by lysing cell membranes. Due to their activity against resistant strains lytic peptides have shown potential as antimicrobials. Their rapid bactericidal mechanism also minimises the possibility of resistance developing.  We have taken advantage of our proprietary and in-depth knowledge of the general lytic peptide pharmacophore to develop synthetic drug-like molecules that retain the positive characteristics of lytic peptides whilst offering excellent stability and low costs of goods. 

More recent research has shown that lytic peptides have a powerful anti-tumour effect. The Lytix anti-cancer peptides cause necrotic degradation and release of danger signals from the tumour leading to an induction of anti-tumour immune responses.  Lytix is developing synthetic peptides that take advantage of these characteristics to produce an entirely new class of cancer therapeutics.